A promising new achievement of Cuban biotechnology to treat Alzheimer's
- Written by Orfilio Peláez
- Published in Health
- Hits: 826
The development of a novel formulation of recombinant human erythropoietin (NeuroEpo) by the Center for Molecular Immunology, in collaboration with others, offers hope in the treatment of this devastating illness.
Given the accelerated aging of the Cuban population, (21.3% 60 years of age and over, at the end of 2020) and the fact that Alzheimer's disease is a key factor in the prevalence of dementia in older adults, scientists are working to obtain drugs that offer hope in the treatment of this devastating illness.
One of the most promising, current research projects underway involves the development of a novel formulation of recombinant human erythropoietin (NeuroEpo), with characteristics similar to those produced by the brain, an achievement of the Center for Molecular Immunology (CIM), in collaboration with the Center for Research and Development of Medicines (Cidem) and other institutions.
Doctor of Science Tania Crombet Ramos, director of Clinical Research at the CIM, detailed to Granma that the medication is administered nasally, making it very convenient and simple for the patient's caregiver.
She emphasized that between 2017 and 2020, different phases of clinical trials were conducted with NeuroEpo to treat Alzheimer's disease, producing results that confirmed its safety and efficacy, with improvements in the degree of cognitive impairment, and a tendency to detain the disease in the mild or moderate stage.
The novel drug is being evaluated by the Center for State Control of Medicines, Equipment and Medical Devices (Cecmed), the Cuban agency responsible for granting authorization to register such products. /Granma
